Document:

Exhibit
10.2 

 

PUT OPTION AGREEMENT

 

AMONG

 

SIFY TECHNOLOGIES LIMITED

 

AND

 

KOTAK SPECIAL SITUATIONS FUND

 

AND

 

SIFY INFINIT SPACES LIMITED

 

DATED: NOVEMBER 1, 2021

 

    	 	 	 

     

    

 

PUT OPTION AGREEMENT

 

This PUT OPTION AGREEMENT (this
“Agreement”) dated November 1, 2021 (“Execution Date”), among:

 

SIFY TECHNOLOGIES LIMITED, a company
incorporated under Companies Act, 1956, and having its registered office at TIDEL Park, 2nd Floor No. 4, Canal Bank
Road, Taramani, Chennai – 600 113, Tamil Nadu, India (hereinafter referred to as the “STL”, which expression
shall unless repugnant to the context or meaning thereof mean and include its successors and assigns) of the FIRST PART;

 

AND

 

KOTAK SPECIAL SITUATIONS FUND, a
trust duly registered under the Applicable Laws of India, acting through its trustee, Vistra ITCL (India) Limited, registered with
the Securities and Exchange Board of India as a Category II Alternative Investment Fund, represented through Kotak Investment Advisors
Limited, a company duly incorporated under the Companies Act 1956 and having its registered office at 27 BKC, 7th Floor, Plot No.
C-27, G Block, Bandra Kurla Complex, Bandra East. Mumbai – 400051 (“Investor”, which expression shall,
unless it be repugnant to the context and meaning thereof, be deemed to mean and include its successors and permitted assigns)
of the SECOND PART;

 

    	 	 	1 

     

    

 

AND

 

SIFY INFINIT SPACES LIMITED, a company
incorporated under the Companies Act, 2013 and having its registered office at 2nd Floor, TIDEL Park No. 4, Rajiv Gandhi Salai,
Taramani, Chennai – 600 113, Tamil Nadu, India (hereinafter referred to as the “SIS” or the “Company”
or the “Confirming Party”, which expression shall unless repugnant to the context or meaning thereof mean and
include its successors and assigns) of the THIRD PART.

 

STL and the Investor shall hereinafter
collectively be referred to as the “Parties” and individually referred to as a “Party”.

 

RECITALS:

 

		(A)	Pursuant to a debenture subscription agreement dated November 1, 2021 between the Investor, SIS
and STL (the “DSA”), the Investor has agreed to subscribe to the Investor CCDs, on the terms and conditions
set forth in the DSA. Executed copy of the DSA is annexed hereto as Annexure I.

 

    	 	 	2 

     

    

  

		(B)	In furtherance of the DSA, the Parties are desirous of entering into this Agreement whereby the
Investor would be granted a put option in relation to the Investor CCDs subscribed by the Investor pursuant to the provisions of
the DSA, in accordance with the terms and conditions of this Agreement. This Agreement shall be treated as part of the Transaction
Documents (as defined in the DSA).

 

		(C)	In consideration of the Investor entering into the Transaction Documents, and SIS confirming and
acknowledging the transaction contemplated herein, STL and the Investor have agreed to undertake its respective rights and obligations
hereinafter contained.

 

		1.	DEFINITIONS AND INTERPRETATION 

 

		1.1.	Definitions

 

Capitalized terms not specifically
defined herein shall, unless the context otherwise requires, have the same meaning ascribed to them under the DSA. Wherever used
in this Agreement, the following terms have the following meanings:

 

“Material Adverse Effect”
means any event, change, development (including any change in Applicable Law), circumstance, effect or other matter that has, or
could reasonably be expected to have, either individually or in the aggregate with all other events, changes, developments, circumstances,
effects or other matters, with or without notice, lapse of time or both, a material adverse effect on: (i) the business,
the assets or liabilities of STL, condition (financial or otherwise), operating results or operations or prospects of the business
taken as a whole; or (ii) the ability of STL to perform their respective obligations under this Agreement or to consummate
the transactions contemplated by this Agreement in a timely manner;

 

“Put CCDs”
means such number of the Investor CCDs subscribed by the Investor in accordance with the terms of the DSA, as the Investor may
specify in a Put Option Notice;

 

“STL Put Price”
shall mean the aggregate of the price per Investor CCD which would entitle the Investor to realise an IRR of [***%] on
the Investor Aggregate Accreted Amount and subject to such revisions as set out in Clause 3.1.

 

“STL Settlement Date”
means the date for settlement of the purchase of the relevant Put CCDs by STL.

 

		1.2.	Interpretation

 

The terms referred to in this
Agreement shall, unless defined otherwise or inconsistent with the context or meaning thereof, bear the meanings ascribed to them
under the relevant statute/legislation

 

		1.2.1.	Reference to statutory provisions shall be construed as meaning
and including references also to any amendment or re-enactment (on or after the Execution Date) for the time being in force and
to all statutory instruments or orders made pursuant to such statutory provisions.

 

		1.2.2.	Any reference to a document in “Agreed Form”
is to a document in a form agreed between the Parties initialled for the purpose of identification by or on behalf of each of them
(in each case with such amendments as may be agreed by or on behalf of the Parties).

 

    	 	 	3 

     

    

 

		1.2.3.	Any reference to “Account”
or “Accounts” shall include the relevant balance sheets and profit and loss
accounts together with all documents which are required by Applicable Law to be annexed to the accounts of the Company, to be laid
before the Company in the general meeting for the relevant Financial Year.

 

		1.2.4.	The words “hereof,”
“herein” and “hereunder”
and words of similar import when used in this Agreement shall refer to this Agreement as a whole and not to any particular provision
of this Agreement. The words “include”, “including”
and “among other things” shall, in all cases, be deemed to be followed by
“without limitation” or “but not limited to”
whether or not they are followed by such phrases or words of like import.

 

		1.2.5.	Words denoting the singular shall include the plural and words
denoting any gender shall include all genders.

 

		1.2.6.	Table of contents, headings, subheadings, titles, subtitles to
clauses, sub-clauses and paragraphs are for information and convenience only and shall not form part of the operative provisions
of this Agreement or the annexures hereto and shall not affect the interpretation or construction of this Agreement.

 

		1.2.7.	References to Recitals, Clauses, Appendices, Annexures, Paragraphs,
Preamble and Schedules are to recitals, appendices and annexures to, and clauses, paragraphs, preamble and schedules of this Agreement,
all of which form part of this Agreement.

 

		1.2.8.	Unless otherwise specified, references to days, months and years
are to calendar days, calendar months and calendar years, respectively.

 

Unless
otherwise specified, time periods within or following which any payment is to be made or act is to be done shall be calculated
by excluding the day on which the period commences and including the day on which the period ends and by extending the period to
the next Business Day if the last day of such period is not a Business Day; and whenever any payment is to be made or action to
be taken under this Agreement is required to be made or taken on a day other than a Business Day, such payment shall be made or
action taken on the next Business Day. 

 

		1.2.9.	All approvals and/or consents to be granted by the Parties under
this Agreement shall be deemed to mean approvals and/or consents in writing. Words “directly or indirectly”
mean directly or indirectly through one or more intermediary Persons or through contractual or other legal arrangements, and “direct
or indirect” have the correlative meanings.

 

		1.2.10.	Where any obligation of a Party under this Agreement (“Subject
Obligation”) requires consent (including from any Governmental Authority) in order for
the Subject Obligation to be performed validly, then the Subject Obligation shall be deemed to include the obligation to apply
for, obtain, maintain and comply with the terms of, all such consents and the time provided for the completion of the Subject Obligation
shall be extended for the time required to obtain such consent, except if and to the extent that the provisions of Applicable Law
or this Agreement require another Party to obtain such consent.

 

		1.2.11.	Any reference to “writing”
shall include printing, typing, lithography, transmissions by facsimile, electronic mail and other means of reproducing words in
visible form but excluding text messaging via mobile/ smart phones.

 

		1.2.12.	The words “include”
and “including” are to be construed without limitation.

 

    	 	 	4 

     

    

 

		1.2.13.	No provisions shall be interpreted in favour of, or against,
any Party by reason of the extent to which such Party or its counsel participated in the drafting hereof or by reason of the extent
to which any such provision is inconsistent with any prior draft hereof.

 

		1.2.14.	If, in calculating a price or an amount, the relevant variables
for such calculation are expressed in different currencies then all such variables for the purposes of such calculation shall be
in Indian Rupees.

 

		1.2.15.	If there is any conflict or inconsistency between a term in the
body of this Agreement and a term in any of the schedules or any other document referred to or otherwise incorporated in this Agreement,
the term in the body of this DSA shall take precedence.

 

		1.2.16.	The Parties agree and undertake that notwithstanding anything
to the contrary contained in this Agreement, the Shareholders shall undertake all such measures as may be required to give effect
to the provisions of this Agreement including but not limited to voting in such manner as may be necessary to give effect to the
provisions of this Agreement.

 

		1.2.17.	To the extent any statement contained in this
Agreement is qualified by the knowledge, belief or awareness of STL,
such statement shall be deemed to include any knowledge, belief or awareness which STL would
have, based on all the data, facts, information by whatever name called, that is within the actual knowledge of any identified
key employee or Director, after exercising reasonable care and diligence, in case of STL.

 

		1.2.18.	The Parties acknowledge and agree that SIS is executing this Agreement
as a confirming party and no other rights / obligations are applicable to SIS.

 

		2.	STL PUT OBLIGATION 

 

		2.1.	STL hereby grants to the Investor, an option (the “STL Put Option Right”) to
sell to STL, the Put CCDs by exercising the STL Put Option Right on or after October 01, 2027, and STL shall be obligated to purchase
from the Investor upon exercise of such STL Put Option Right, all of the Put CCDs (as specified by the Investor in the relevant
STL Put Option Notice) in accordance with the terms of this Agreement. In addition to the foregoing, upon occurrence of, (i) an
Event of Default as defined in the DSA; or (ii) if the Company fails to provide exit to the Investor by way of Qualified
IPO or Alternate Listing by the Exit Long Stop Date, as envisaged in the DSA or (iii) breach by STL of any of its obligation or
covenants under this Agreement, the Investor shall have the right to exercise the STL Put Option Right, on the date of occurrence
of such Event of Default or on the Exit Long Stop Date.

 

		2.2.	The STL Put Option Right may be exercised by the Investor by delivery to STL of a put option notice,
which shall specify the number of Put CCDs, bank account into which the STL Put Price shall be paid, the applicable STL Settlement
Date and the STL Put Price (“STL Put Option Notice”). STL may acquire these Put CCDs either by itself or through
any other entity nominated by STL.

 

		2.3.	In case of Event of Default as per the DSA or if the Company fails to provide exit to the Investor
by way of Qualified IPO or Alternate Listing by the Exit Long Stop Date, as envisaged in the DSA or (iii) breach by STL of any
of its obligation or covenants under this Agreement, STL shall pay to the Investor no later than 90 (ninety) days from the date
of STL Put Option Notice, the entire STL Put Price into the bank account (subject to applicable withholding taxes) specified by
the Investor in the STL Put Option Notice.

 

    	 	 	5 

     

    

 

		2.4.	If the Investor exercises the STL Put Option Right otherwise than, (i) upon occurrence
of an Event of Default as defined in the DSA; or (ii) if the Company fails to provide exit to the Investor by way of
Qualified IPO or Alternate Listing by the Exit Long Stop Date, as envisaged in the DSA or (iii) breach by STL of any of
its obligation or covenants under this Agreement, then the following shall apply:

 

		2.4.1.	STL First Settlement Date:

 

		(i)	On the STL First Settlement Date, that is the date of completion of 12 (twelve) months from the
date of the STL Put Option Notice, STL shall pay to the Investor, into the bank account specified by the Investor, 33.33% of the
STL Put Price (“First Instalment STL Put Price”), in immediately available funds. The First Instalment STL Put
Price shall be paid without any deductions whatsoever for any fees, Taxes, duties, costs or other charges howsoever called (all
of which shall be borne by STL).

 

		(ii)	The Investor shall, immediately upon the receipt of the First Instalment STL Put Price, transfer
to STL (or its assignee), free of all Encumbrances, the Put CCDs, as specified in the STL Put Option Notice and in proportion of
the First Instalment STL Put Price paid by STL, and the debenture certificates, if any, evidencing title to the Put CCDs together
with such duly executed and stamped instruments of transfer, if any, as required by the Applicable Laws to effect the transfer.

 

		2.4.2.	STL Second Settlement Date:

 

		(i)	On the STL Second Settlement Date, that is the date of completion of 24 (twenty-four) months from
the date of the STL Put Option Notice, STL shall pay to the Investor, into the bank account specified by the Investor, 33.33% of
the STL Put Price (“Second Instalment STL Put Price”), in immediately available funds. The Second Instalment
STL Put Price shall be paid without any deductions whatsoever for any fees, Taxes, duties, costs or other charges howsoever called
(all of which shall be borne by STL).

 

		(ii)	The Investor shall, immediately upon the receipt of the Second Instalment STL Put Price, transfer
to STL (or its assignee), free of all Encumbrances, Put CCDs, as specified in the STL Put Option Notice and in proportion of the
Second Instalment STL Put Price paid by STL, and the debenture certificates, if any, evidencing title to the Put CCDs together
with such duly executed and stamped instruments of transfer, if any, as required by the Applicable Laws to effect the transfer.

 

		2.4.3.	STL Third Settlement Date:

 

		(i)	On the STL Third Settlement Date, that is the date of completion of 36 (thirty-six) months from
the date of the STL Put Option Notice, STL shall pay to the Investor, into the bank account specified by the Investor, the balance
33.33% of the STL Put Price (“Third Instalment STL Put Price”), in immediately available funds. The Third Instalment
STL Put Price shall be paid without any deductions whatsoever for any fees, Taxes, duties, costs or other charges howsoever called
(all of which shall be borne by STL).

 

    	 	 	6 

     

    

 

		(ii)	The Investor shall, immediately upon the receipt of the Third Instalment STL Put Price, transfer
to STL (or its assignee), free of all Encumbrances, Put CCDs, as specified in the STL Put Option Notice and in proportion of the
Third Instalment STL Put Price paid by STL, and the certificates, if any, evidencing title to the Put CCDs together with such duly
executed and stamped instruments of transfer, if any, as required by the Applicable Laws to effect the transfer (“STL
Third Settlement Completion”).

 

		2.5.	Upon the STL Third Settlement Completion, the Investor’s obligations in respect of the transfer
of the Put CCDs shall be fully and finally discharged and STL shall be responsible for completing any and all filings and formalities
to be complied with under Applicable Law in respect of such transfer, provided that the Investor shall extend assistance to STL
and the Company, as required to ensure the valid transfer of the Put CCDs to STL. Notwithstanding anything set out in the Transaction
Documents, all income tax applicable on the STL Put Price shall be borne by the Investor. Until the relevant STL Settlement Date,
the Investor shall be entitled to all of its rights as a debenture holder (or rights attached to such Put CCDs), whether under
the DSA, Applicable Law or otherwise. The calculation by the Investor of the STL Put Price shall be binding and conclusive for
all purposes, absent manifest error.

 

		2.6.	All payments to be made by STL and/or the Company to the Investor under or in connection with the
Put CCDs and/or under any Transaction Document, shall be made free and clear of and without any tax deduction, unless STL and/or
the Company is required to make tax deduction under the Applicable Laws. In the event any withholding taxes are required to be
deducted by STL and/or the Company as per Applicable Law, the same shall be borne by the Investor.

 

		3.	FAILURE TO PERFORM BY STL

 

		3.1.	Without prejudice to the Investor’s rights and remedies as set out in the DSA in case of
occurrence of an Event of Default or if the Investor has not been provided with exit by way Qualified IPO or Alternate Listing
by the Exit Long Stop Date as contemplated by the DSA or STL is in breach of any of its obligations or covenants under this Agreement,
the STL Put Price shall mean the aggregate of the price per Investor CCD which would entitle the Investor to realise an IRR of
[***]% on the Investor Aggregate Accreted Amount.

 

		3.2.	Without prejudice to any remedies available to the Investor under this Agreement or otherwise,
if after the Investor has delivered to STL a STL Put Option Notice, STL fails to purchase and pay, as herein provided, for all
or any of the Put CCDs included in such STL Put Option Notice, the Investor shall have the right (but not the obligation), in its
sole discretion and notwithstanding any obligations owed by the Investor to STL under the DSA to the contrary, the performance
by the Investor of which STL hereby waives, to sell, transfer or otherwise dispose of any or all of such unpurchased and unpaid
Put CCDs to any Person; provided, however, that STL shall remain obligated to pay to the Investor the corresponding STL Put Price
and any late payment charge due thereon, as reduced by an amount equal to the net proceeds, if any, actually received by the Investor
as a result of such sale, transfer or other disposition of the relevant Put CCDs, with the amount of such proceeds.

 

    	 	 	7 

     

    

  

		4.	OBLIGATIONS OF STL

 

		4.1.	The obligations of STL hereunder are irrevocable and shall not be terminated, suspended or affected
in any manner by the deterioration of the financial situation or the interruption of the operations of STL or the Company (whether
by condemnation, expropriation, nationalization or otherwise) or the insolvency of the Company or STL or the filing of any bankruptcy
proceeding or any similar proceeding by or against the Company or STL or any other circumstances whatsoever. For the avoidance
of doubt, the obligations of STL and the rights of the Investor hereunder shall automatically terminate (without the requirement
of any further action or deed) and be of no further force or effect immediately upon the termination of the DSA, or, consummation
of a Qualified IPO or Alternate Listing resulting in the listing of the securities of the Company being listed on the Recognised
Stock Exchange provided that no such termination of any provision of this Agreement shall affect or prejudice the rights and/or
obligations of any Party which have accrued or been incurred prior to such termination.

 

		4.2.	If the Investor is agreeable to exit at the Exit Purchase Price, then STL, shall directly or indirectly,
through any other third Person have the right to purchase all of the Investor CCDs held by the Investor in the Company at the Exit
Purchase Price instead of undertaking Qualified IPO as contemplated in Clause 17.5 of the DSA or Alternate Listing as contemplated
in Clause 17.6 of the DSA. STL shall give to the Investor a written notice within 7 (seven) days of the 3 (three) Investment Bankers
providing the IPO indicative price bands to the Company as per Clause 17.5.1(ii) of the DSA, for purchasing all of the Investor
CCDs at the Exit Purchase Price (“STL Exit Purchase Notice”). Upon receipt of the STL Exit Purchase Notice, the Investor
shall have the obligation to communicate its acceptance at the earliest to STL, in writing, but no later than 90 (ninety) days
from the receipt of the Exit Purchase Notice (“STL Exit Purchase Acceptance Notice”). Upon receipt of the Exit Purchase
Acceptance Notice, STL shall have the obligation to purchase all of the Investor CCDs in the Company no later than 90 (ninety)
days from the date of the STL Exit Purchase Acceptance Notice. The Exit Purchase Price, the Parties shall take the average of the
cap price of the 3 (three) IPO Indicative Price Bands determined by the Investment Bankers (as per Clause 17.5.1(ii) of the DSA
(such average being the “Exit Purchase Price”).

 

		5.	CONSENTS AND APPROVALS; FURTHER ASSURANCES 

 

STL shall take and cause the
Company to take all such action and do, perform, execute and deliver, in a due and expeditious manner, all acts, deeds and documents
as shall be necessary from time to time to cause the effective performance of STL’s obligations, under this Agreement and
the DSA, including but not limited to voting or providing a written consent with respect to any of the voting shares, rights or
interests of the Company in order to adopt or reject any corporate or shareholder resolutions necessary to effect the provisions
of this Agreement and the DSA and making, or causing to be made, all governmental, regulatory and administrative filings with any
appropriate Governmental Authority. STL, in its capacity as a controlling Shareholder of the Company, undertakes to take such action,
as is necessary to prevent any amendment of the charter documents of the Company / Restated Charter Documents of the Company and/or
the taking of any action by the Company, the effect of which would be to restrict or prevent the sale, transfer or disposition
of any Put CCDs in accordance with the provisions of this Agreement.

 

		6.	COVENANTS

 

		6.1.	STL shall provide to the Investor a net worth certificate certifying its net worth, as on the First
Closing Date as of March 31, 2021 (as annexed hereto as Annexure II) and as on 31st day of March every year, so long as the
put obligations have not been settled in accordance with terms hereof.

 

		6.2.	STL undertakes that its shareholding in SIS shall not go below 50% of the share capital of SIS,
without the prior written consent of the Investor.

 

    	 	 	8 

     

    

 

		6.3.	STL shall take all such action and do, perform, execute and deliver, in a due and expeditious manner,
all acts, deeds and documents as shall be necessary from time to time to cause the effective performance of the STL's obligations,
under this Agreement and the DSA and making, or causing to be made, all governmental, regulatory and administrative filings with
any appropriate Governmental Authority.

 

		6.4.	STL represents, warrants and covenants that it has obtained necessary board and shareholders approvals
as may be required to perform, execute and deliver STL’s obligations under this Agreement and upon exercise of Put Option
Right by the Investor it shall be an irrevocable payment obligation on part of STL to pay the Put Price in accordance with Clause
2 and 3 of this Agreement.

 

		6.5.	No Material Adverse Effect has occurred on STL on the First Closing Date or any subsequent closing
date(s) (as set out in the DSA) with respect to the allotment and subscription of the Investor CCDs.

 

		6.6.	STL shall, during the subsistence of this Agreement, ensure that the business of datacentre shall
be conducted only through the Company or through a joint venture company where the Company and customers / potential customers
/ DC operators are the only shareholders/ partners and no other entity comprising the Promoter Group and its Affiliates shall be
a shareholder of such joint venture, provided that if the Proposed Merger of SDMS has not been completed prior to Strategic Sale
Exit then the Strategic Equity Valuation should include the valuation of SDMS.

 

		6.7.	If the directors of STL are added to wilful defaulter list by the relevant Governmental Authority,
STL and its shareholders shall take immediate steps forthwith to remove such Person from the board of directors of STL.

 

		6.8.	Information Covenants: STL shall provide to the Investor in relation to STL:

 

		6.8.1.	promptly upon becoming aware of them, the details of any event which may have a Material Adverse
Effect on STL;

 

		6.8.2.	promptly, notice of any change in its authorised signatories (in connection with the Transaction
Documents), signed by one of its directors or its company secretary, whose specimen signature has previously been provided to the
Investor accompanied (where relevant) by a specimen signature of each new signatory;

 

		6.8.3.	promptly, all letters, notices, petitions, plaints, and other documents relating to any suit, action,
petition, arbitration, litigation or other legal proceeding of any nature whatsoever commenced in relation to any winding-up and/or
in relation to any Insolvency Event by or against STL promptly, all letters, notices, petitions, plaints, and other documents relating
to any suit, action, petition, arbitration, litigation or other legal proceeding of any nature whatsoever received from the relevant
Governmental Authority;

 

		6.8.4.	promptly, all letters, notices, petitions, plaints, and other documents relating to any suit, action,
petition, arbitration, litigation or other legal proceeding of any nature whatsoever commenced (including in relation to any winding-up
and/or in relation to any Insolvency Event) by or against STL, which would have an adverse impact on the obligations of STL under
the Transaction Documents, or the Security created thereunder or this Agreement;

 

    	 	 	9 

     

    

 

		6.8.5.	promptly, all letters, notices, petitions, plaints, and other documents relating to any suit, action,
petition, arbitration, litigation or other legal proceeding of any nature whatsoever commenced (including in relation to any winding-up
and/or in relation to any Insolvency Event) by or against STL involving a liability exceeding INR 30,00,00,000 (Rupees thirty crores
only);

 

		6.8.6.	promptly, notice(s) of any purported/estimated loss or damage exceeding INR 30,00,00,000 (Rupees
thirty crores only) which may be incurred and/or suffered by STL due to the occurrence of any force majeure events and/or any events
and circumstances which adversely affect the performance by STL of its respective obligations or covenants under any agreements/documents
including any acts of God i.e., fire, storms, pandemics, floods, earthquake or lightning, war, hostilities, terrorist acts, riots,
civil commotion or disturbances affecting STL and/or any of its respective properties/assets and/or sabotage or explosions affecting
STL and/or any of its properties/assets, in relation to which STL has not obtained adequate insurance cover;

 

		6.8.7.	copies of notices of the board meetings and shareholders’ meetings of STL to the Investor,
which relate to borrowings, investments and fund raise above INR 30,00,00,000 (Rupees thirty crores only) respectively, simultaneously
with the same being circulated to the directors / shareholders of STL, each certified by the chairman or the chief executive officer
or the company secretary of STL as being true, accurate and not misleading. For the avoidance of doubt the Investor shall only
be entitled to copies of the board meetings and/or shareholders’ meetings of STL which relate to direct or indirect corporate
restructuring (including change of management), fund raise, related party transactions, intercorporate loans or deposits or any
other issue that may directly or indirectly affect the rights of the Investor or value of the Investment made by the Investor under
DSA and this Agreement;

 

		6.8.8.	promptly, all details in respect of declaration of any default in respect of any Financial Indebtedness
of STL by any bank or financial institution or in case of declaration of any default/ breach of any covenants or undertakings by
STL under any financing documents entered into by the Company with such bank or financial institution;

 

		6.8.9.	at least within 3 (three) Business Days upon effecting any change in composition of the board of
directors of STL (subject to Applicable Laws), the details of proposed changes;

 

		6.8.10.	at least 3 (three) Business Days prior to effecting any sale/ transfer/ disposal of assets of STL
of an aggregate value exceeding INR 30,00,00,000 (Rupees thirty crores only) in any year, the details of the assets proposed to
be sold/ transferred / disposed off; and

 

		6.8.11.	as soon as it becomes available, but in any event within 180 (one hundred and eighty) days after
the end of each Financial Year, the audited financial statements (both consolidated and standalone, wherever applicable) of STL.

 

		7.	CONFIRMATION

 

The Company acknowledges the
transaction contemplated herein.

 

		8.	REPRESENTATIONS AND WARRANTIES

 

		8.1.	Representations and Warranties of STL: STL represents and warrants to the Investor that
each of the representations and warranties as set out below are, true, accurate, complete and not misleading as on the date of
this Agreement and shall continue to be true, accurate, complete and not misleading as on the First Closing Date, any subsequent
closing date(s) with respect to the allotment and subscription of Additional CCDs and subsistence of this Agreement.

 

    	 	 	10 

     

    

 

		8.1.1.	STL is a duly organised and validly existing company incorporated in India under the Act.

 

		8.1.2.	STL has full power and authority to execute and deliver this Agreement (to which it is a party)
and to complete the transactions contemplated thereby. The constitutional documents of STL include provisions which authorises
it to execute and deliver this Agreement (to which it is a party) and exercise its rights and perform its obligations under this
Agreement (to which it is a party).

 

		8.1.3.	STL has obtained all necessary corporate authority for the due execution and delivery of this Agreement
(to which it is a party) and exercise its rights and perform its obligations under this Agreement (to which it is a party). The
obligations expressed to be assumed by STL in this Agreement to which it is a party are legal, valid, binding and enforceable in
accordance with the provisions of Applicable Law.

 

		8.1.4.	The entry into and performance by STL of, and the transactions contemplated by, this Agreement
to which it is a party, do not conflict with any Applicable Law, its constitutional documents; or any agreement or instrument binding
upon it or any of their assets.

 

		8.1.5.	The entire share capital of STL is held by the Persons including the ultimate beneficial owners,
the details of whom will be provided by STL as annexed hereto as Annexure III.

 

		8.1.6.	STL has sufficient financial resources to perform, complete and honour STL’s obligation as
contemplated hereunder on exercise of STL Put Option Right by the Investor.

 

		8.2.	Representations and Warranties of the Investor: Investor represents and warrants to STL
that each of the representations and warranties as set out below are, true, accurate, complete and not misleading as on the date
of this Agreement and shall continue to be true, accurate, complete and not misleading during the subsistence of this Agreement:

 

		8.2.1.	Investor has full power and the capacity and authority to enter into and execute and deliver this
Agreement and to perform all of its obligations hereunder.

 

		8.2.2.	This Agreement, upon execution, constitutes legal, valid and binding obligations of the Investor
and is enforceable in accordance with its respective terms.

 

		8.2.3.	The execution and delivery of this Agreement by it and the performance of its obligations under
this Agreement do not conflict with any Applicable Law, rule or regulation applicable to it, any provisions of its constitutional
documents (if applicable) or any contract.

 

		9.	TERM AND TERMINATION

 

This Agreement shall become effective
and binding on the Parties on and from the Execution Date till the termination of the DSA or as otherwise set out in this Agreement.

 

    	 	 	11 

     

    

 

		10.	SPECIFIC PERFORMANCE

 

The Investor and STL acknowledge
and agree that the Investor would be irreparably damaged if any of the provisions of this Agreement are not performed in accordance
with their specific terms and that any breach of this Agreement by STL could not be adequately compensated in all cases by monetary
damages alone. Accordingly, in addition to any other right or remedy to which the Investor may be entitled, at law or in equity,
it shall be entitled to enforce any provision of this Agreement by a decree of specific performance and to temporary, preliminary
and permanent injunctive relief to prevent breaches or threatened breaches of any of the provisions of this Agreement, without
posting any bond or other undertaking.

 

		11.	GOVERNING LAW AND JURISDICTION

 

This Agreement shall be governed
by, and interpreted in accordance with, the laws of India. Subject to the provisions of Clause 12, the courts at Chennai, India
shall have non-exclusive jurisdiction in relation to the enforcement of any awards provided for under Clause 12 and in relation
to any applications for conservatory or similar interim reliefs arising out of this Agreement.

 

		12.	ARBITRATION OF DISPUTES

 

		12.1.	Any dispute arising out of or in connection with this Agreement, including any question regarding
its existence, validity or termination (a "Dispute"), shall be referred to and finally resolved by arbitration
in accordance with the SIAC Rules 2016 (as amended from time to time), which Rules are deemed to be incorporated by reference into
this Agreement, and the arbitration will be administered by the SIAC.

 

		12.2.	The Party(ies) issuing a notice referring the Dispute to arbitration shall be referred to
as the “Claimant(s)” and the party(ies) against whom the Dispute has arisen shall be referred to as the “Respondent(s)”. The
arbitration tribunal (the "Tribunal") shall consist of three arbitrators. The Claimant(s) shall appoint one arbitrator,
and the Respondent(s) shall appoint one arbitrator. The third arbitrator, who shall be the presiding arbitrator of the tribunal,
shall be appointed by the two-party-nominated arbitrators within 15 (fifteen) Business Days of the last of their appointments.
If the third arbitrator has not been agreed within this time period, the third arbitrator shall be appointed by the President of
the SIAC Court pursuant to Rule 11.3 of the SIAC Rules 2016.

 

		12.3.	The seat and venue of arbitration shall be Singapore. However, in order to save costs, the
Parties have agreed to have the venue, for the conduct the arbitral proceedings at Mumbai.

 

		12.4.	The language to be used in the arbitral proceedings shall be English.

 

		12.5.	Any award of the Tribunal shall be made in writing and shall be final and binding on the parties
from the day it is made and no further appeal shall lie against the said award of the Tribunal. The Parties undertake to carry
out the award without delay.

 

		12.6.	The Parties waive any right to apply to any court of law and/or other judicial authority to determine
any preliminary point of law and/or review any question of law and/or the merits, insofar as such waiver may validly be made. 
The Parties shall not be deemed, however, to have waived any right to apply for the setting aside of any award to the extent allowed
by the law of the seat of arbitration.  Nothing in this sub-clause shall be construed as preventing any party from seeking
conservatory or interim relief from any court of competent jurisdiction.

 

		12.7.	Any Party to this Agreement, may in accordance with the SIAC Rules 2016, be joined to any arbitration
commenced under this Agreement. Each Party to this Agreement hereby consents, for the purposes of the SIAC Rules 2016, to such
joinder. The Parties further agree to consolidate arbitrations, in relation to other disputes on matters connected to this Agreement,
into a single arbitration and proceed in accordance to the provisions hereof.

 

    	 	 	12 

     

    

 

		12.8.	The Parties hereby agree to expressly exclude the applicability of Part I of the (Indian) Arbitration
and Conciliation Act, 1996 (save and except section 9, section 27 and section 37 thereof) to any arbitration conducted pursuant
to this Clause 12.

 

		13.	FURTHER ASSURANCES

 

Each Party shall give such further
assurance, provide such further information, take such further actions and execute and deliver such further documents and instruments
as are, in each case, within its power to give, provide and take so as to give full force and effect to the provisions of this
Agreement.

 

		14.	NOTICES

 

		14.1.	Any notice or other writing to be given by any Party to the other Parties in connection with or
under this Agreement or for the purposes of this Agreement shall be in writing and in English. Any such notice may be given by
personal delivery or by courier or by fax (followed by courier) or by electronic email (followed by courier) addressed as follows:

 

If to STL: 

 

Attention: S. Athmanandha
Perumal, Head Legal

 

Address: “Tidel
Park”, 2nd Floor, No.4, Rajiv Gandhi Salai, Taramani, Chennai – 600113

 

Telephone: 044-22540770

 

E-mail: athmanandha.perumal@sifycorp.com

 

If to the Investor:

 

Attention: Mr. Eshwar Karra

Address: 27 BKC, 7th Floor, Plot
No. C-27, G Block, Bandra Kurla Complex, Bandra East. Mumbai – 400051

Telephone: +91 022-43360704

E-mail: eshwar.karra@kotak.com

 

If to the Company:

 

Attention: V. Ramanujan,
Chief Financial Officer

 

Address: Tidel Park”,
2nd Floor, No.4, Rajiv Gandhi Salai, Taramani, Chennai - 600 113

 

Telephone: 044-22540770

 

E-mail: ramanujan.veeraraghavan@sifycorp.com

 

    	 	 	13 

     

    

 

or to such other address as any
Party shall designate by written notice to the other Parties and shall be deemed to be given only when delivered by personal delivery
or by courier or by fax (followed by courier) or by electronic mail (followed by courier) at the abovementioned address. The effective
date of any notice shall be the earlier of: (i) actual receipt; and (ii) deemed receipt as detailed below in Clause
14.2.

 

		14.2.	Any notice pursuant to this Clause 14 is deemed given:

 

		14.2.1.	If delivered personally: on the date of delivery provided that if such day is not a Business
Day then the notice shall be deemed to have been given and received on the next Business Day in the country of the recipient following
such day;

 

		14.2.2.	If delivered by courier: 2 (two) days after being mailed by courier, provided such day is
a Business Day failing which the immediately following Business Day;

 

		14.2.3.	If transmitted by fax: on the date of transmission provided that, if transmission is after
business hours, then the notice shall be deemed to have been given and received on the next Business Day in the country of the
recipient following the date of transmission; or

 

		14.2.4.	If transmitted by email (and wherever required, followed by courier): 3 (three) days after
being mailed by courier, provided such day is a Business Day failing which the immediately following Business Day.

 

		14.3.	All notices, counter notices or other instruments or designations delivered by the Investor in
relation to this Agreement shall be effective if, signed by the Investor’s representative.

 

		15.	COSTS AND EXPENSES

 

Each Party is responsible for
any costs and expenses incurred by it in relation to the execution of this Agreement and any transactions contemplated hereunder.
STL shall be responsible for the payment of any and all stamp duties related to: (i) the execution of this Agreement; and
(ii) transfer of the Put CCDs, under the terms of this Agreement.

 

		16.	ASSIGNMENT

 

		16.1.	The Investor shall be entitled to assign/Transfer the Put CCDs, its rights, duties, benefits and
obligations under this Agreement to any Person who shall have acquired Put CCDs from the Investor in accordance with the terms
of this Agreement and the DSA, subject to execution of a Deed of Adherence for Investor Transferee by such Person.

 

		16.2.	This Agreement shall be binding upon and inure to the benefit of the Parties and their respective
heirs, successors, permitted assigns, executors and administrators.

 

		17.	WAIVER

 

No waiver of any right under
this Agreement shall be effective unless in writing. Unless expressly stated otherwise a waiver shall be effective only in the
circumstances for which it is given. No delay or omission by any Party in exercising any right or remedy provided by the Applicable
Law or under this Agreement shall constitute a waiver of such right or remedy. The single or partial exercise of a right or remedy
under this Agreement shall not preclude any other nor restrict any further exercise of any such right or remedy.

 

		18.	AMENDMENTS

 

This Agreement may not be amended,
modified or supplemented except by a written instrument executed by each of the Parties.

 

    	 	 	14 

     

    

 

		19.	NO PARTNERSHIP

 

No Party shall act as an agent
of the other Party or have any authority to act for or to bind the other Party.

 

		20.	PARTIAL INVALIDITY

 

If any provision of this Agreement
or the application thereof to any Person or circumstance shall be invalid or unenforceable to any extent for any reason including
by reason of any Applicable Law, the remainder of this Agreement and the application of such provision to persons or circumstances
other than those as to which it is held invalid or unenforceable shall not be affected thereby, and each provision of this Agreement
shall be valid and enforceable to the fullest extent permitted by Applicable Law. Any invalid or unenforceable provision of this
Agreement shall be replaced with a provision, which is valid and enforceable and most nearly reflects the original intent of the
invalid and unenforceable provision.

 

		21.	SEVERABILITY

 

If any provision of this Agreement
is adjudged to be void or unenforceable, the same shall in no way affect any other provision of this Agreement, or its validity
or enforceability, and the unenforceable provision shall be performed to the extent valid and enforceable.

 

		22.	COUNTERPARTS

 

This Agreement may be executed
in 1 (one) or more counterparts, each of which when so executed and delivered shall be deemed an original, but all of which together
shall constitute one and the same instrument and any Party may execute this Agreement by signing any 1 (one) or more of such originals
or counterparts. This Agreement may be executed and delivered by facsimile or by .pdf file and upon such delivery the facsimile
or .pdf signature will be deemed to have the same effect as if the original signature had been delivered to the other party.

 

		23.	LAST PARTY EXECUTION

 

This Agreement shall be deemed
to have been executed and shall come into force on the date when it is accepted and executed by the Company, who shall be the last
party executing this Agreement.

 

(Signature Pages Follow)

 

    	 	 	15 

     

    

 

IN WITHNESS WHEREOF, the Parties
hereto, acting through their duly authorized representatives, have caused this Agreement to be signed in their respective names,
as of the date first written above:

 

SIGNED AND DELIVERED

 

By the within named “STL”,

 

Sify Technologies Limited

by the hand of Mr. S. Athmanandha Perumal

 

______________________________,

its Authorised Signatory.

 

    	 	 	16 

     

    

 

SIGNED AND DELIVERED

 

By the within named “Investor”,

Kotak Special Situations Fund

by the hand of Mr. Eshwar Karra

 

______________________________,

its Authorised Signatory.

 

And

 

By the within named “Investor”,

Kotak Special Situations Fund

by the hand of Mr. Rahul Shah

 

______________________________,

its Authorised Signatory.

 

    	 	 	17 

     

    

 

SIGNED AND DELIVERED

 

By the within named “SIS”
or “Company”,

 

Sify Infinit Spaces Limited 

by the hand of Mr. V. Ramanujan

 

______________________________,

its Authorised Signatory.

 

    	 	 	18 

     

    

  

ANNEXURE I

 

Signed copy of the Debenture Subscription
Agreement dated November 1, 2021

(to be attached separately) 

 

    	 	 	19 

     

    

 

ANNEXURE II

 

Net Worth Certificate of STL

 

Part A

Net Worth as on March 31, 2021

(to be attached separately)

 

Part B

Unaudited Net Worth as on September 30,
2021

(to be attached separately)

 

    	 	 	20 

     

    

  

ANNEXURE III

 

Shareholding pattern of STL and details
of ultimate beneficial owners of STL

 

	 	 	No. of Shares	 	 	% of Shareholding	 	 	Paid-up Capital (in INR)	 
	Foreign Holding	 	 	 	 	 	 	 	 	 	 	 	 
	ADRs held by Citibank, New York, Depositary  (Listed)	 	 	2,84,50,591	 	 	 	15.59	 	 	 	28,45,05,910	 
	Infinity Capital Ventures, LP, USA   (Unlisted)	 	 	1,39,02,860	 	 	 	7.62	 	 	 	13,90,28,600	 
	Vegesna Family Trust, USA  (Listed)	 	 	6,20,466	 	 	 	0.34	 	 	 	62,04,660	 
	Total	 	 	4,29,73,917	 	 	 	23.55	 	 	 	42,97,39,170	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Resident Holding	 	 	 	 	 	 	 	 	 	 	 	 
	Infinity Satcom Universal Private Limited	 	 	1,45,30,000	 	 	 	7.96	 	 	 	14,53,00,000	 
	Ramanand Core Investment Company Private Limited	 	 	12,50,00,000	 	 	 	68.49	 	 	 	1,25,00,00,000	 
	Others	 	 	652	 	 	 	0.00	 	 	 	6,520	 
	Total	 	 	13,95,30,652	 	 	 	76.45	 	 	 	1,39,53,06,520	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Grand Total	 	 	18,25,04,569	 	 	 	100.00	 	 	 	1,82,50,45,690	 

 

Shareholding pattern of Ramanand
Core Investment Company Private Limited

 

	 	 	No. of Shares	 	 	% of Shareholding	 	 	Paid-up Capital (in INR)	 
	Equity Shares
	Raju Vegesna InfoTech Industries Pvt Ltd.	 	 	4,493,953	 	 	 	75.13	%	 	 	44,939,530	 
	Ramanand Developers Ltd.	 	 	1,259,675	 	 	 	21.06	%	 	 	12,596,750	 
	Infinity Satcom Universal Pvt Ltd.	 	 	228,166	 	 	 	3.81	%	 	 	2,281,660	 
	V Ananda Raju	 	 	1	 	 	 	0	%	 	 	10	 
	V Raghu Ram Raju	 	 	1	 	 	 	0	%	 	 	10	 
	Total	 	 	5,981,796	 	 	 	100.00	%	 	 	59,817,960	 
	Preference Shares	 	 	 	 	 	 	 	 	 	 	 	 
	Raju Vegesna InfoTech Industries Pvt Ltd.	 	 	450,000	 	 	 	 	 	 	 	45,000,000	 

 

    	 	 	21 

     

    

  

Shareholding pattern of Raju
Vegesna InfoTech Industries Pvt Ltd.

 

	 	 	No. of Shares	 	 	% of Shareholding	 	 	Paid-up Capital (in INR)	 
	Raju Vegesna	 	 	5,321,629	 	 	 	45	%	 	 	53,216,290	 
	Infinit Satcom Universal Pvt. Ltd.	 	 	6,438,500	 	 	 	55	%	 	 	64,385,000	 
	Vegesna Ananda Raju	 	 	50	 	 	 	0	%	 	 	500	 
	Vegesna Raghu Rama Raju	 	 	50	 	 	 	0	%	 	 	500	 
	Total	 	 	11,760,229	 	 	 	100	%	 	 	117,602,290	 

 

Shareholding pattern of Infinity Satcom
Universal Pvt Ltd

 

	 	 	No. of Shares	 	 	% of Shareholding	 	 	Paid-up Capital (in INR)	 
	Vegesna Ananta Koti Raju	 	 	3,534,845	 	 	 	84	%	 	 	35,348,450	 
	Aarti Realtors (India) Pvt. Ltd.	 	 	195,571	 	 	 	5	%	 	 	1,955,710	 
	Vegesna Ananda Raju	 	 	495,000	 	 	 	12	%	 	 	4,950,000	 
	Vegesna Raghu Rama Raju	 	 	5,000	 	 	 	0	%	 	 	50,000	 
	Total	 	 	4,230,416	 	 	 	100	%	 	 	42,304,160	 

 

    	 	 	22Exhibit 10.1
​
EXECUTIVE EMPLOYMENT AGREEMENT
​
This EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) is entered into effective August 3, 2021 (the “Effective Date”), by and between Harout Semerjian (“Executive”) and GlycoMimetics, Inc. (the “Company”).
WHEREAS, the Company desires to employ Executive to provide personal services to the Company, and Executive wishes to be employed by the Company and provide personal services to the Company in return for certain compensation and benefits.
Accordingly, in consideration of the mutual promises and covenants contained herein, the parties agree to the following:
1.EMPLOYMENT BY THE COMPANY.
1.1Term.  The term of employment hereunder will be for the four year period commencing on the Effective Date and ending on the fourth anniversary of the Effective Date, subject to termination prior thereto pursuant to Sections 5, 6, 7, 8 or 9 below.  Unless the Company gives notice of its intent not to renew Executive’s employment hereunder, or Executive gives written notice to the Company of Executive’s determination not to renew Executive’s service and employment hereunder, in any case at least one year prior to the fourth anniversary of the Effective Date, this Agreement, and Executive’s employment by the Company hereunder, shall be renewed for one year from that anniversary.  Thereafter, unless the Company or Executive gives written notice of determination not to renew at least one year prior to the next succeeding anniversary of the Effective Date, this Agreement shall be renewed for one year from that anniversary.  The term “Service Period” shall mean the four year period provided for in this Section 1.1 and any extension thereof, or any shorter period resulting from any termination of service under Sections 5, 6, 7, 8 or 9 hereof.
1.2Position and Effective Date.  Executive’s employment with the Company shall commence on the Effective Date.  Prior to the Effective Date or in the event that Executive does not commence employment with the Company under this Agreement, the Company shall have no obligation to provide Executive with compensation and benefits (including, but not limited to, the “Severance Benefits” stated in Sections 9.2 or 9.3). Executive will be appointed as the Company’s President and Chief Executive Officer of the Company effective as of August 6, 2021. Executive will be appointed as a member of the Board of Directors of the Company (the “Board”) effective as of August 6, 2021 and thereafter shall be renominated for election by the stockholders to serve on the Board with each term of Board service during the term of Executive’s employment as Chief Executive Officer.  During the term of Executive’s employment with the Company, Executive will devote Executive’s best efforts and substantially all of Executive’s business time and attention to the business of the Company.
1.3Duties.  Executive will report to the Chairperson (the “Chair”) of the Board and/or such other Board officers or committees designated by the Chair, performing such duties as are normally associated with Executive’s positions as President and Chief Executive Officer and such duties consistent therewith as are assigned to Executive from time to time by the Chair, subject to the oversight and direction of the Chair or any applicable designee;
​

1

​
provided, however, that unless Executive is incapacitated by illness or injury from fully performing his duties or otherwise provides his consent, Executive will not be required to report to an Executive Chair. Executive shall perform Executive’s duties under this Agreement principally out of the Company’s Rockville, Maryland location, or such other location as assigned.  In addition, Executive shall make such business trips to such places as may be necessary or advisable for the efficient operations of the Company.
1.4Company Policies and Benefits; Indemnification.  The employment relationship between the parties shall also be subject to the Company’s personnel policies and procedures as they may be interpreted, adopted, revised or deleted from time to time in the Company’s sole discretion.  Executive will be eligible to participate on the same basis as similarly situated employees in the Company’s benefit plans in effect from time to time during Executive’s employment.  All matters of eligibility for coverage or benefits under any benefit plan shall be determined in accordance with the provisions of such plan.  The Company reserves the right to change, alter, or terminate any benefit plan in its sole discretion.  Notwithstanding the foregoing, in the event that the terms of this Agreement differ from or are in conflict with the Company’s general employment policies or practices, this Agreement shall control.  Executive shall be eligible for four (4) weeks’ vacation each calendar year (prorated for 2021) to be administered in accordance with the Company’s vacation policy as may be in effect from time to time.  The Company and Executive will enter into the Company’s customary indemnification agreement applicable to directors in respect of Executive’s services as an officer and member of the Board.
1.5Time to be Devoted to Service.  Except for reasonable vacations, absences due to temporary illness, and activities that may be mutually agreed to by the parties, Executive shall devote Executive’s entire time, attention and energies during normal business hours and such evenings and weekends as may be reasonably required for the discharge of Executive’s duties to the business of the Company during the Service Period.  During the Service Period, Executive will not be engaged in any other business activity, which, in the reasonable judgment of the Board, conflicts with the duties of Executive hereunder, whether or not such activity is pursued for gain, profit or other pecuniary advantage.  The Company further acknowledges and agrees that, subject to the prior written approval by a majority of the Board (which majority shall exclude Executive if Executive is a then current member of the Board) and consistent with the terms of the Employee Proprietary Information Agreement (as defined in Section 3 below), Executive may serve on the boards of directors and advisory boards of other companies provided that such service does not interfere with the performance of Executive’s duties hereunder.
		2.
	COMPENSATION.

2.1Base Salary.  Executive shall receive for Executive’s services to be rendered hereunder an initial annualized base salary of $595,000.00, subject to review and adjustment from time to time by the Company in its sole discretion and payable subject to standard federal and state payroll withholding requirements in accordance with Company’s standard payroll practices (“Base Salary”).
​

2

​
2.2Sign-On Bonus.  The Company will pay Executive a cash sign-on bonus in the aggregate amount of $200,000 (“Sign-On Bonus”), which shall be payable in two equal instalments (less applicable tax withholdings), with: (a) the first installment paid within thirty (30) days of the Effective Date and (b) the second installment paid on the first anniversary of the Effective Date, provided Executive is employed by the Company on such date.  If Executive resigns without Good Reason (as defined below) or is terminated for Cause (as defined below) (i) in the case of the first such installment, prior the first anniversary of the Effective Date and (ii) in the case of the second such installment, prior to the second anniversary of the Effective Date, Executive shall be obligated to, and hereby agrees to, repay a prorated portion of the net, after-tax, amount of such installment paid to Executive, which shall be pro-rated based on the fraction, the numerator of which is the number of days from date of termination of Executive’s employment until the first anniversary (in the case of the first installment) or the second anniversary (in the case of the second installment) of the Effective Date and the denominator of which is 365.  Executive agrees that if he is obligated to repay any portion of the Sign-On Bonus, the Company may deduct, in accordance with applicable law, any such repayment amount from any payments the Company owes Executive, including but not limited to any regular payroll amount and any expense payments.  Executive further agrees to pay to the Company, within thirty (30) days of the effective termination date, any remaining unpaid balance of the Sign-On Bonus due from Executive not covered by such deductions.
2.3Annual Bonus.  Executive shall be eligible to be awarded an annual cash bonus pursuant to the Company’s annual performance bonus plan (“Bonus”), with the target amount of such bonus equal to fifty-five percent (55%) of Executive’s Base Salary during the then current bonus year (“Target Bonus”), subject to review and adjustment from time to time by the Company in its sole discretion, payable subject to standard federal and state payroll withholding requirements.  Whether or not Executive is awarded any Bonus will be dependent upon (a) the actual achievement by Executive and the Company of the applicable individual and corporate performance goals, as determined by the Board’s Compensation Committee in its sole discretion, and (b) Executive’s continuous performance of services to the Company through the date any Bonus is paid (except as provided in Sections 9.1 and 9.2 below).  The amount of any Bonus awarded may be greater or lesser than the Target Bonus and may be zero.  The annual period over which performance is measured for purposes of this bonus is January 1 through December 31.  Any Bonus awarded pursuant to this Section 2.3 will be paid on or before March 15 of the year following the year for which it is awarded.  Executive must be employed on the date bonuses are paid in order to be eligible for any bonus.  In the event of termination of Executive’s employment, no bonus, prorated or otherwise, will be paid for the year in which termination occurs.  For calendar year 2021, Executive’s Target Bonus shall not be less than a Target Bonus amount but shall be prorated based on the number of days during the calendar year in which Executive is employed by the Company.
2.4Initial Stock Option.  On the Effective Date, Executive will be granted a time-based option to purchase 1,098,400 shares of the Company’s common stock (“Common Stock”) (the “Initial Option”).  The Initial Option will vest according to the following schedule: 25% of the total shares underlying the Initial Option will vest on the first anniversary of the Effective Date, and the remaining 75% of the total shares of Common Stock underlying the Initial Option will vest in substantially equal monthly installments over the three year period thereafter, subject to Executive’s Continuous Service (as defined in the GlycoMimetics, Inc.
​

3

​
Inducement Plan (the “Plan”)) as of each such date.  The Initial Option will be granted pursuant and subject to the Plan and the Company’s standard form of stock option agreement, modified to conform with the terms of this Agreement.  The Initial Option shall have an exercise price per share equal to  the Fair Market Value (as defined in the Plan) of the Common Stock on the grant date and a 10-year term.
2.5Milestone Stock Option.  On the Effective Date, Executive will be granted a milestone-based option to purchase 549,200 shares of the Company’s Common Stock (the “Milestone Option”).  The Milestone Option will vest upon achievement of milestones as follows: (a) one-half of the Milestone Option will vest upon FDA approval of uproleselan in patients with relapsed/refractory acute myeloid leukemia and (b) the other one-half of the Milestone Option will vest upon the first commercial sale of uproleselan in the United States or abroad, subject, in the case of (a) or (b), to Executive’s Continuous Service (as defined in the Company’s Plan) as of each such date for the respective portion of the Milestone Option to vest.  The Milestone Option will be granted pursuant and subject to the Plan and the Company’s standard form of stock option agreement, modified to conform with the terms of this Agreement.  The Milestone Option shall have an exercise price per share equal to the Fair Market Value of the Common Stock on the grant date and a 10-year term.
2.6Expense Reimbursement.  The Company will reimburse Executive for reasonable business expenses in accordance with the Company’s standard expense reimbursement policy; provided, however, that such reimbursable expenses will not include any expenses related to Executive’s commute to the Company’s office, Executive’s housing or living accommodations or Executive’s relocation of his primary residence to the Rockville, Maryland area.  For the avoidance of doubt, to the extent that any reimbursements payable to Executive are subject to the provisions of Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”): (a) any such reimbursements will be paid no later than December 31 of the year following the year in which the expense was incurred, (b) the amount of expenses reimbursed in one year will not affect the amount eligible for reimbursement in any subsequent year, and (c) the right to reimbursement under this Agreement will not be subject to liquidation or exchange for another benefit.
3.PROPRIETARY INFORMATION, INVENTIONS, NON-COMPETITION AND NON-SOLICITATION OBLIGATIONS.  The parties hereto are entering into an Employee Confidential Information, Inventions, Non-Solicitation and Non-Competition Agreement attached hereto as Exhibit A (the “Employee Proprietary Information Agreement”), which may be amended by the parties from time to time without regard to this Agreement.  The Employee Proprietary Information Agreement contains provisions that are intended by the parties to survive and do survive termination or expiration of this Agreement.
​
4.NO CONFLICT WITH EXISTING OBLIGATIONS.  Executive represents that Executive’s performance of all the terms of this Agreement and as an Executive of the Company do not and will not breach any agreement or obligation of any kind made prior to Executive’s employment by the Company, including agreements or obligations Executive may have with other employers or entities for which Executive has provided services.  Executive has not entered into, and Executive agrees that Executive will not enter into, any agreement or obligation, either written or oral, in conflict herewith.
​
​

4

​
5.TERMINATION DUE TO DEATH OR DISABILITY.
5.1Death or Disability.  If Executive dies while employed pursuant to this Agreement, then all obligations of the parties hereunder shall terminate immediately.  If Executive is unable due to a physical or mental condition to perform the essential functions of his/her position with or without reasonable accommodation for ninety (90) consecutive days or for one-hundred and eighty (180) days in the aggregate during any twelve (12) month period or based on the written certification by two licensed physicians of the likely continuation of such condition for either such period (such condition being herein referred to as “Disability”), the Company, at its option, may terminate Executive’s employment under this Agreement immediately upon giving Executive notice to that effect.  This definition shall be interpreted and applied consistent with the Americans with Disabilities Act, the Family and Medical Leave Act, and other applicable law.  Termination pursuant to this Section 5 is hereinafter referred to as a “Death or Disability Termination”.
5.2Substitution.  The Board may designate another employee to act in Executive’s place during any period of Executive’s Disability during the Service Period.  Notwithstanding any such designation, Executive shall receive Executive’s Base Salary and benefits in accordance with Sections 1.4 and 2 of this Agreement until Executive becomes eligible for disability income under the Company’s disability income insurance (if any) or until the termination of Executive’s employment, whichever shall first occur.
5.3Disability Income Payments.  While receiving disability income payments under the Company’s disability income insurance (if any), Executive shall not be entitled to receive any Base Salary, but shall continue to be eligible to participate in all other compensation and benefits in accordance with Sections 1.4 and 2  until the date of Executive’s termination.  Notwithstanding the foregoing and in accordance with the Company’s benefit plans, Executive may be ineligible for coverage as an employee under the Company’s group health insurance plan during the period of Executive’s Disability, in which case continued coverage will be based on eligibility for COBRA or applicable state continuation coverage.  All matters of eligibility for coverage or benefits under any benefit plan shall be determined in accordance with the provisions of such plan.
5.4Verification of Disability.  If any question shall arise as to whether during any period Executive is disabled through any illness, injury, accident or condition of either a physical or psychological nature so as to be unable to perform substantially all of Executive’s duties and responsibilities hereunder, Executive may, and at the request of the Company shall, submit to a medical examination by one or more licensed physicians selected by the Company to whom Executive or Executive’s guardian has no reasonable objection to determine whether Executive is so disabled and such determination shall for the purposes of this Agreement be conclusive of the issue.  If such question shall arise and Executive shall fail to submit to such medical examination, the Company’s determination of the issue shall be binding on Executive.
6.TERMINATION FOR CAUSE.  The Board may terminate the employment of Executive hereunder at any time for “Cause” (such termination being hereinafter referred to as a
​

5

​
“Termination for Cause”) by giving Executive notice of such termination as described in Section 9.5, and upon the giving of such notice termination shall take effect immediately.  For the purpose of this Section 6, “Cause” will mean that the Board has determined in its reasonable discretion that any of the following occurred: (a) Executive’s breach of fiduciary duty or substantial misconduct with respect to the business and affairs of the Company or any subsidiary or affiliate thereof, (b) Executive’s gross negligence or failure to substantially perform Executive’s duties which can reasonably be expected to materially adversely affect the business or affairs of the Company, the Company or any subsidiary or affiliate thereof, (c) Executive’s material breach of this Agreement or of any provision of the Employee Proprietary Information Agreement which, to the extent curable, is not cured within 15 days after written notice thereof is given to Executive, (d) the commission by Executive of an act involving moral turpitude or fraud, (e) Executive’s conviction of any felony, or of any misdemeanor involving fraud, theft, embezzlement, forgery or moral turpitude, (f) other misconduct by Executive that is materially harmful to the business or reputation of the Company, including but not limited to conduct found to be in violation of the Company’s policies prohibiting harassment or discrimination, or (g) the expiration of this Agreement.
7.TERMINATION WITHOUT CAUSE.  The Board may terminate the employment of Executive hereunder at any time without “Cause” (such termination being hereinafter called a “Termination Without Cause”) by giving Executive notice of such termination as described in Section 9.5.  Executive’s termination of employment under this Section 7 will take effect immediately upon the giving of such notice.
8.RESIGNATION BY EXECUTIVE.
8.1Without Good Reason.  Any resignation by Executive other than for Good Reason (as defined below) will be referred to hereinafter as a “Resignation”.  A Resignation will be deemed to be effective following notice under Section 9.5.
8.2With Good Reason.  Provided Executive has not previously been notified of the Company’s intention to terminate Executive’s employment, Executive may resign from employment with the Company for Good Reason (as defined below) by giving the Company written notice of such termination in compliance with Section 9.5 and provided that such notice specifies:  (i) the basis for termination; and (ii) the effective date of termination (such termination being hereinafter referred to as a “Termination for Good Reason”).  For purposes of this Agreement, the term “Good Reason” shall mean any of the following without Executive’s prior written consent: (w) any material diminution of Executive’s title, duties or responsibilities hereunder (except in each case in connection with a Termination for Cause or as a result of Executive’s death or Disability), or, the assignment to Executive of duties or responsibilities that are materially inconsistent with Executive’s then position; provided, however, that the acquisition of the Company and subsequent conversion of the Company to a division or unit of the acquiring company will not by itself result in a diminution of Executive’s duties or responsibilities; (x) a material reduction in Executive’s Base Salary, which the parties agree is a reduction of at least 10% of Executive’s Base Salary (unless pursuant to a salary reduction program applicable generally to the Company’s senior executives); (y) any material breach of the Agreement by the Company which is not cured within 15 business days after written notice thereof is given to the Company; or (z) a relocation of Executive from the Company’s principal
​

6

​
office to a location more than 35 miles from the location of the Company’s principal office, other than on required travel by Executive on the Company’s business or on a temporary basis not to exceed a period equal to two calendar months; provided, however, that any such termination by Executive shall only be deemed for Good Reason pursuant to this definition if:  (1) Executive gives the Company written notice of intent to terminate for Good Reason within 30 days following the first occurrence of the condition(s) that Executive believes constitute(s) Good Reason, which notice shall describe such condition(s); (2) the Company fails to remedy such condition(s) within 30 days following receipt of the written notice (the “Cure Period”); (3) the Company has not, prior to receiving such notice from Executive, already informed Executive that Executive’s employment with the Company is being terminated; and (4) Executive voluntarily terminates Executive’s employment within 30 days following the end of the Cure Period.
9.EFFECT OF TERMINATION OF EMPLOYMENT.
9.1Resignation, Death or Disability Termination, or a Termination for Cause.  Upon the termination of Executive’s employment hereunder pursuant to a Resignation, Death or Disability Termination, or a Termination for Cause, neither Executive nor Executive’s beneficiary or estate will receive severance payments, or any other severance compensation or benefit, or have any further rights or claims against the Company, its affiliates, or its subsidiaries under this Agreement except to receive:
(a)the accrued but unpaid portion of Executive’s then current Base Salary, computed on a pro-rata basis to the date of such termination, subject to the Company’s standard payroll policies;
(b)all compensation and benefits payable to Executive based on Executive’s then current participation in any compensation or benefit plan, program or arrangement through the date of termination; and
(c)reimbursement for any expenses for which Executive shall not have theretofore been reimbursed as provided in the Company’s standard expense reimbursement policy.
9.2Termination Without Cause or for Good Reason (Other Than Change in Control).  Upon the termination of Executive’s employment hereunder pursuant to a Termination Without Cause or a Termination for Good Reason (other than in connection with a Change in Control (as defined below)), neither Executive nor Executive’s beneficiary or estate will have any further rights or claims against the Company, its affiliates or its subsidiaries under this Agreement except to receive:
(a)a termination payment equal to that provided for in Section 9.1 hereto; and
(b)if Executive executes a general release in favor of the Company, substantially in the form attached hereto as Exhibit B (the “Release”), and subject to Section 9.2(c) (the date that the Release becomes effective and may no longer be revoked by Executive is referred to as the “Release Date”), then the Company shall pay to Executive the following
​

7

​
severance benefits (such benefits referred to as “Severance Benefits”): (i) continuation of Executive’s then current Base Salary for a period of eighteen (18) months from the Release Date (such applicable period is referred to as the “Severance Period”), less applicable withholdings and deductions (“Severance Pay”), paid in equal installments  beginning on the Company’s first regularly scheduled payroll date that is at least sixty (60) days following the Release Date (the “Severance Pay Commencement Date”), with the remaining installments occurring on the Company’s regularly scheduled payroll dates thereafter; provided, however, that on the Severance Pay Commencement Date, the Company will pay in a lump sum the aggregate amount of the Severance Pay that the Company would have paid Executive through such date had the payments commenced on the first regular payroll date following the Separation from Service (as defined below) through the Severance Pay Commencement Date, with the balance paid thereafter on the applicable schedule described above; (ii) a lump sum payment equivalent to the the unpaid Bonus Executive would have otherwise earned under Section 2.3 for the calendar year prior to that in which Executive’s termination or resignation under this Section 9.2 occurs had he remained employed through the date bonuses are regularly paid to senior executives; (iii) payment of the premiums of Executive’s group health insurance COBRA continuation coverage, including coverage for Executive’s eligible dependents, for a maximum period of eighteen (18) months following Executive’s Termination Without Cause or a Termination for Good Reason (other than in connection with a Change in Control (as defined below)) (such period subject to the qualifications of this Section 9.2(b) referred to as “COBRA Payment Period”); provided, however, that (a) the Company shall pay premiums for Executive and Executive’s eligible dependents only for coverage for which Executive and Executive’s eligible dependents were enrolled immediately prior to the Termination Without Cause or Termination for Good Reason; (b) the Company’s obligation to pay such premiums shall cease immediately upon Executive’s eligibility for comparable group health insurance provided by a new employer of Executive or upon Executive no longer being eligible for COBRA during the COBRA Payment Period; and (c) the Company’s obligation to pay such premiums shall be contingent on Executive’s timely election of continued group health insurance coverage under COBRA. Vesting of any unvested stock options and/or other equity securities shall cease on the date of termination following Executive’s Termination Without Cause or a Termination for Good Reason (other than in connection with a Change in Control (as defined below)).  Notwithstanding the foregoing, if at any time the Company determines, in its sole discretion, that the payment of the COBRA premiums would result in a violation of the nondiscrimination rules of Section 105(h)(2) of the Code or any statute or regulation of similar effect (including, without limitation, the 2010 Patient Protection and Affordable Care Act, as amended by the 2010 Health Care and Education Reconciliation Act), then in lieu of providing the COBRA premiums, the Company will instead pay Executive, on the first day of each month of the remainder of the COBRA Payment Period, a fully taxable cash payment equal to the COBRA premiums for that month, subject to applicable tax withholdings and deductions (such amount, the “Special Severance Payment”).
(c)To receive the Severance Benefits pursuant to Section 9.2(b), Executive’s termination or resignation must constitute a “separation from service” (as defined under Treasury Regulation Section 1.409A-1(h)) (“Separation from Service”) and Executive must execute and allow the Release to become effective within 60 days of Executive’s termination or resignation.  Executive’s ability to receive the Severance Benefits pursuant to Section 9.2(b) is further conditioned upon Executive: returning all Company property; complying with post-termination obligations under this Agreement and the Employee Proprietary
​

8

​
Information Agreement, and complying with the Release including without limitation any non-disparagement and confidentiality provisions contained therein.  The Severance Benefits provided to Executive pursuant to Section 9.2(b) are in lieu of, and not in addition to, any benefits to which Executive may otherwise be entitled under any Company severance plan, policy or program.
(d)The damages (if any) caused to Executive by a Termination Without Cause or a Termination for Good Reason would be difficult to ascertain; therefore, the Severance Benefits for which Executive is eligible pursuant to Section 9.2(b) above in exchange for the Release is agreed to by the parties as liquidated damages, to serve as full compensation, and not a penalty.
9.3Change in Control Severance Benefits.
​
(a)In the event that the Company (or any surviving or acquiring corporation) terminates Executive’s employment for a Termination Without Cause or Executive resigns in connection with a Termination for Good Reason within 12 months following the effective date of a Change in Control (“Change in Control Termination”), and upon compliance with Section 9.2(c) above, Executive shall be eligible to receive the following Change in Control severance benefits instead of the Severance Benefits set forth in Section 9.2 above: (i) a lump-sum cash payment in an amount equal to Executive’s annual Base Salary then in effect for a period of eighteen (18) months, less applicable withholdings and deductions, paid on the 60th day following the Change in Control Termination; (ii) an amount equal to 1.5 times (1.5x) Executive’s then current annual Target Bonus paid on the 60th day following the Change in Control Termination; and (iii) the Company (or any surviving or acquiring corporation) shall pay the premiums of Executive’s group health insurance COBRA continuation coverage, including coverage for Executive’s eligible dependents, during the eighteen (18) months following a Change in Control Termination (such period subject to the qualifications of this Section 9.3(a) referred to as “CIC COBRA Payment Period”); provided, however, that (a) the Company (or any surviving or acquiring corporation) shall pay premiums for Executive and Executive’s eligible dependents only for coverage for which Executive and Executive’s eligible dependents were enrolled immediately prior to the Change in Control Termination; and (b) the Company’s (or any surviving or acquiring corporation’s) obligation to pay such premiums shall cease immediately upon Executive’s eligibility for comparable group health insurance provided by a new employer of Executive or upon Executive no longer being eligible for COBRA during the CIC COBRA Payment Period; and (c) the Company’s obligation to pay such premiums shall be contingent on Executive’s timely election of continued group health insurance coverage under COBRA.  Executive agrees that the Company’s (or any surviving or acquiring corporation’s) payment of health insurance premiums will satisfy the Company’s obligations under COBRA for the period provided.  No insurance premium payments will be made following the effective date of Executive’s coverage by a health insurance plan of a subsequent employer.  For the balance of the period that Executive is entitled to coverage under federal COBRA law, if any, Executive shall be entitled to maintain such coverage at Executive’s own expense.  Notwithstanding the foregoing, if at any time the Company determines, in its sole discretion, that the payment of the COBRA premiums would result in a violation of the nondiscrimination rules of Section 105(h)(2) of the Code or any statute or regulation of similar effect (including, without limitation, the 2010 Patient Protection and Affordable Care Act, as amended by the 2010 Health
​

9

​
Care and Education Reconciliation Act), then in lieu of providing the COBRA premiums, the Company will instead pay Executive, on the first day of each month of the remainder of the CIC COBRA Payment Period, the Special Severance Payment.
(b)To receive the payments in Section 9.3(a), Executive’s termination or resignation must constitute a Separation from Service (as defined under Treasury Regulation Section 1.409A-1(h)) and Executive must execute and allow the Release to become effective within 60 days of Executive’s termination or resignation.  Executive’s ability to receive benefits pursuant to Section 9.3(a) is further conditioned upon Executive: returning all Company property; complying with Executive’s post-termination obligations under this Agreement and the Employee Proprietary Information Agreement, and complying with the Release including without limitation any non-disparagement and confidentiality provisions contained therein.
(c)In addition, notwithstanding anything contained in Executive’s award agreements to the contrary, upon a Change in Control Termination Executive shall receive accelerated vesting of all then unvested shares of the Company’s Common Stock subject to outstanding stock options, restricted stock units and any other equity incentive awards that Executive then may have, if any; provided, however, that unvested shares subject to Executive’s outstanding stock options shall only accelerate if Executive executes the Release within the timeframe provided by the Company and Executive’s stock options shall remain outstanding following the date of Executive’s Change in Control Termination if and to the extent necessary to give effect to this Section 9.3(c) subject to earlier termination under the terms of the equity plan under which such stock options were granted and the original maximum term of the award (without regard to Executive’s termination).
(d)As used in this Agreement, a “Change in Control” is defined as the first to occur of the following: (a) a sale, lease, exchange or other transfer in one transaction or a series of related transactions of all or substantially all of the assets of the Company (other than the transfer of the Company’s assets to a majority-owned subsidiary corporation); (b) a merger or consolidation in which the Company is not the surviving corporation (unless the holders of the Company’s outstanding voting stock immediately prior to such transaction own, immediately after such transaction, securities representing at least fifty percent (50%) of the voting power of the corporation or other entity surviving such transaction); (c) a reverse merger in which the Company is the surviving corporation but the shares of the Company’s common stock outstanding immediately preceding the merger are converted by virtue of the merger into other property, whether in the form of securities, cash or otherwise (unless the holders of the Company’s outstanding voting stock immediately prior to such transaction own, immediately after such transaction, securities representing at least fifty percent (50%) of the voting power of the Company); or (d) any transaction or series of related transactions in which in excess of fifty percent (50%) of the Company’s voting power is transferred.  Notwithstanding the foregoing, to the extent that the Company determines that any of the payments or benefits under this Agreement that are payable in connection with a Change in Control constitute deferred compensation under Section 409A that may only be paid on a qualifying transaction (that is, they are not “exempt” under 409A), the foregoing definition of Change in Control shall apply only to the extent the transaction also meets the definition used for purposes of Treasury Regulation Section 1.409A-3(a)(5), that is, as defined under Treasury Regulation Section 1.409A-3(i)(5).
​

10

​
9.4Parachute Taxes.
(a)If any payment or benefit Executive would receive from the Company or otherwise in connection with a Change of Control or other similar transaction (“Payment”) would (i) constitute a “parachute payment” within the meaning of Section 280G of the Code, and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then such Payment will be equal to the Reduced Amount.  The “Reduced Amount” will be either (x) the largest portion of the Payment that would result in no portion of the Payment being subject to the Excise Tax, or (y) the largest portion, up to and including the total, of the Payment, whichever amount ((x) or (y)), after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in Executive’s receipt of the greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax.  If a Reduced Amount will give rise to the greater after tax benefit, the reduction in the Payments will occur in the following order: (a) reduction of cash payments; (b) cancellation of accelerated vesting of equity awards other than stock options; (c) cancellation of accelerated vesting of stock options; and (d) reduction of other benefits paid to Executive.  Within any such category of payments and benefits (that is, (a), (b), (c) or (d)), a reduction will occur first with respect to amounts that are not “deferred compensation” within the meaning of Section 409A and then with respect to amounts that are.  In the event that acceleration of compensation from Executive’s equity awards is to be reduced, such acceleration of vesting will be canceled, subject to the immediately preceding sentence, in the reverse order of the date of grant.
(b)The registered public accounting firm engaged by the Company for general audit purposes as of the day prior to the effective date of the event described in Section 280G(b)(2)(A)(i) of the Code will perform the foregoing calculations.  If the registered public accounting firm so engaged by the Company is serving as accountant or auditor for the acquirer or is otherwise unable or unwilling to perform the calculations, the Company will appoint a nationally recognized firm that has expertise in these calculations to make the determinations required hereunder.  The Company will bear all expenses with respect to the determinations by such independent registered public accounting firm required to be made hereunder.  The firm engaged to make the determinations hereunder will provide its calculations, together with detailed supporting documentation, to the Company and Executive within 30 calendar days after the date on which Executive’s right to a Payment is triggered (if requested at that time by the Company or Executive) or such other time as reasonably requested by the Company or Executive.  Any good faith determinations of the independent registered public accounting firm made hereunder will be final, binding and conclusive upon the Company and Executive.
9.5Notice; Effective Date of Termination.
(a)Termination of Executive’s employment pursuant to this Agreement shall be effective on the earliest of:
(i)immediately after the Company gives notice to Executive of Executive’s Termination for Cause or Termination Without Cause, unless pursuant to Section 6(c) in which case 15 days after notice if not cured or unless the Company specifies a later date, in which case, termination shall be effective as of such later date;
​

11

​
(ii)immediately upon Executive’s death;
(iii)immediately after the Company gives notice to Executive of Executive’s termination on account of Executive’s Disability, unless the Company specifies a later date, in which case, termination shall be effective as of such later date, provided that Executive has not returned to the full time performance of Executive’s duties prior to such date;
(iv)10 days after Executive gives written notice to the Company of Executive’s Resignation; provided that the Company may set a termination date at any time between the date of notice and the date of resignation, in which case Executive’s resignation shall be effective as of such other date.  Executive will receive compensation through any required notice period; or
(v)the date set forth in Section 8.2 above for a Termination for Good Reason.
(b)In the event notice of a termination under subsections (a)(i), (iii) and (iv) is given orally, at the other party’s request, the party giving notice must provide written confirmation of such notice within 5 business days of the request in compliance with the requirement of Section 10.1 below.
9.6Cooperation With Company After Termination of Employment. Following termination of Executive’s employment for any reason, Executive shall fully cooperate with the Company in all matters relating to the winding up of Executive’s pending work including, but not limited to, any litigation in which the Company is involved, and the orderly transfer of any such pending work to such other employees as may be designated by the Company.  The Company will pay (or reimburse) Executive’s reasonable expenses (including travel expenses) incurred in connection with his obligations under this Section 9.6.  For purposes of Code Section 409A, such payment or reimbursement shall occur not later than December 31 of the calendar year following the calendar year in which incurred.
9.7Application of Section 409A.  It is intended that all of the benefits and payments under this Agreement satisfy, to the greatest extent possible, the exemptions from the application of Code Section 409A provided under Treasury Regulations 1.409A-1(b)(4) and 1.409A-1(b)(9), and this Agreement will be construed to the greatest extent possible as consistent with those provisions.  If not so exempt, this Agreement (and any definitions hereunder) will be construed in a manner that complies with Section 409A, and incorporates by reference all required definitions and payment terms.  For purposes of Code Section 409A (including, without limitation, for purposes of Treasury Regulation Section 1.409A-2(b)(2)(iii)), Executive’s right to receive any installment payments under this Agreement (whether severance payments, reimbursements or otherwise) will be treated as a right to receive a series of separate payments and, accordingly, each installment payment hereunder will at all times be considered a separate and distinct payment.  Notwithstanding any provision to the contrary in this Agreement, if Executive is deemed by the Company at the time of Executive’s Separation from Service to be a “specified employee” for purposes of Code Section 409A(a)(2)(B)(i), and if any of the payments upon Separation from Service set forth herein and/or under any other agreement with the Company are deemed to be “deferred compensation”, then if delayed commencement of any
​

12

​
portion of such payments is required to avoid a prohibited distribution under Code Section 409A(a)(2)(B)(i) and the related adverse taxation under Section 409A, the timing of the payments upon a Separation from Service will be delayed as follows: on the earlier to occur of (i) the date that is six months and one day after the effective date of Executive’s Separation from Service, and (ii) the date of Executive’s death (such earlier date, the “Delayed Initial Payment Date”), the Company will (A) pay to Executive a lump sum amount equal to the sum of the payments upon Separation from Service that Executive would otherwise have received through the Delayed Initial Payment Date if the commencement of the payments had not been delayed pursuant to this paragraph, and (B) commence paying the balance of the payments in accordance with the applicable payment schedules set forth above.  No interest will be due on any amounts so deferred.  To the extent that any severance payments or benefits payable to Executive pursuant to this Agreement are not otherwise exempt from the application of Code Section 409A, then, if the period during which Executive may consider and sign the Release spans two calendar years, the payment of severance will not be made or begin until the later calendar year.
10.GENERAL PROVISIONS.
10.1Notices.  Any notices required hereunder to be in writing shall be deemed effectively given: (a) upon personal delivery to the party to be notified, (b) when sent by electronic mail or confirmed facsimile if sent during normal business hours of the recipient, and if not, then on the next business day, (c) 5 days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) 1 day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt.  All communications shall be sent to the Company, “Attention Chair of the Board,” at its primary office location and to Executive at Executive’s address as listed on the Company payroll, or at such other address as the Company or Executive may designate by 10 days advance written notice to the other.
10.2Severability.  Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction, but this Agreement will be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provisions had never been contained herein.
10.3Survival.  Provisions of this Agreement which by their terms must survive the termination of this Agreement in order to effectuate the intent of the parties will survive any such termination, whether by expiration of the term, termination of Executive’s employment, or otherwise, for such period as may be appropriate under the circumstances.
10.4Waiver.  If either party should waive any breach of any provisions of this Agreement, Executive or the Company shall not thereby be deemed to have waived any preceding or succeeding breach of the same or any other provision of this Agreement.
10.5Complete Agreement.  This Agreement (and the exhibits and agreements referenced herein) constitutes the entire agreement between Executive and the Company with
​

13

​
regard to the subject matter hereof.  This Agreement is the complete, final, and exclusive embodiment of their agreement with regard to this subject matter and supersedes any prior oral discussions or written communications and agreements.  This Agreement is entered into without reliance on any promise or representation other than those expressly contained herein, and it cannot be modified or amended except in writing signed by Executive and an authorized officer of the Company.  The parties will enter into a separate Employee Proprietary Information Agreement and have entered or may enter into separate agreements related to stock awards.  These separate agreements govern other aspects of the relationship between the parties, have or may have provisions that survive termination of Executive’s employment under this Agreement, may be amended or superseded by the parties without regard to this Agreement and are enforceable according to their terms without regard to the enforcement provision of this Agreement.
10.6Further Assurances.  Executive agrees to execute, acknowledge, seal and deliver such further assurances, documents, applications, agreements and instruments, and to take such further actions, as the Company may reasonably request in order to accomplish the purposes of this Agreement.
10.7Counterparts.  This Agreement may be executed in separate counterparts, any one of which need not contain signatures of more than one party, but all of which taken together will constitute one and the same Agreement.
10.8Headings.  The headings of the sections hereof are inserted for convenience only and shall not be deemed to constitute a part hereof nor to affect the meaning thereof.
10.9Successors and Assigns.  This Agreement is intended to bind and inure to the benefit of and be enforceable by Executive and the Company, and their respective successors, assigns, heirs, executors and administrators, except that Executive may not assign any of Executive’s duties hereunder and may not assign any of Executive’s rights hereunder without the written consent of the Company, which shall not be withheld unreasonably.
10.10Choice of Law.  All questions concerning the construction, validity and interpretation of this Agreement will be governed by the law of the State of Maryland, without giving effect to choice of law principles.  Executive and the Company hereby expressly consent to the personal jurisdiction and venue of the state and federal courts located in the State of Maryland for any claims or suits arising from or related to this Agreement.
[Signature page follows]
​
​

14

​
IN WITNESS WHEREOF, the parties have executed this Executive Employment Agreement on the day and year first written above.
​
	/s/

	​

	​

	GLYCOMIMETICS, INC. 
	    
	EXECUTIVE 

	​
	​
	​

	​
	​
	​

	/s/ Timothy Pearson
	​
	/s/ Harout Semerjian

	(Signature)
	​
	(Signature)

	​
	​
	​

	By: Timothy Pearson
	​
	By: Harout Semerjian

	Title: Chair, Board of Directors
	​
	​

​
​

Signature Page to Executive Employment Agreement

​
Exhibit A
​
Employee Proprietary Information Agreement
​
(see following pages)
​
​

Exhibit A to Executive Employment Agreement

​
Exhibit B
​
Release Agreement
​
(see following pages)
​
​

Exhibit B to Executive Employment Agreement

​
Release Agreement
​
This Release Agreement (“Release”) is made by and between GlycoMimetics, Inc. (the “Company”) and Harout Semerjian (“you”).  You and the Company entered into an Executive Employment Agreement dated August 3, 2021 (the “Employment Agreement”).  You and the Company hereby further agree as follows:
​
1.A blank copy of this Release was attached to the Employment Agreement as Exhibit B.
2.Severance Payments.  If your employment was terminated by the Company for a Termination Without Cause, a Termination for Good Reason, or a Change in Control Termination (as defined in the Employment Agreement) in accordance with Section 9 of the Employment Agreement, then in consideration for your execution, return and non-revocation of this Release, following the Release Date (as defined in Section 3 below) the Company will provide severance benefits to you as follows: [described benefits and payment schedule].
3.Release by You.  In exchange for the payments and other consideration under this Release, to which you would not otherwise be entitled, and except as otherwise set forth in this Release, you hereby generally and completely release, acquit and forever discharge the Company, its parents and subsidiaries, and its and their officers, directors, managers, partners, agents, servants, employees, attorneys, shareholders, successors, assigns and affiliates (the “Releasees”), of and from any and all claims, liabilities, demands, causes of action, costs, expenses, attorneys fees, damages, indemnities and obligations of every kind and nature, in law, equity, or otherwise, both known and unknown, suspected and unsuspected, disclosed and undisclosed, arising out of or in any way related to agreements, events, acts or conduct at any time prior to and including the execution date of this Release, including but not limited to:  all such claims and demands directly or indirectly arising out of or in any way connected with your employment with the Company or the termination of that employment; claims or demands related to salary, bonuses, commissions, stock, stock options, or any other ownership interests in the Company, vacation pay, fringe benefits, expense reimbursements, severance pay, or any other form of compensation; claims pursuant to any federal, state or local law, statute, or cause of action; tort law; or contract law (individually a “Claim” and collectively “Claims”).  The Claims you are releasing and waiving in this Release include, but are not limited to, any and all Claims that the Company, its parents and subsidiaries, and its and their respective officers, directors, agents, servants, employees, attorneys, shareholders, successors, assigns or affiliates:
·has violated its personnel policies, handbooks, contracts of employment, or covenants of good faith and fair dealing;
·has discriminated against you on the basis of age, race, color, sex (including sexual harassment), national origin, ancestry, disability, religion, sexual orientation, marital status, parental status, source of income, entitlement to benefits, any union activities or other protected category in violation of any local, state or federal law, constitution, ordinance, or regulation, including but not limited to: the Age Discrimination in Employment Act, as amended (“ADEA”); Title VII of the Civil Rights Act of 1964, as amended; 42 U.S.C. § 1981, as amended; the Civil Rights Act of 1866;
​

1

​
the Fair Employment Practice Act of Maryland, Md. Code Ann., State Government, Title 20; the Worker Adjustment Retraining and Notification Act; the Equal Pay Act; the Americans With Disabilities Act; the Family Medical Leave Act; the Occupational Safety and Health Act; the Immigration Reform and Control Act; the Uniform Services Employment and Reemployment Rights Act of 1994, as amended; Section 510 of the Employee Retirement Income Security Act; and the National Labor Relations Act;
·has violated any statute, public policy or common law (including but not limited to claims for retaliatory discharge; negligent hiring, retention or supervision; defamation; intentional or negligent infliction of emotional distress and/or mental anguish; intentional interference with contract; negligence; detrimental reliance; loss of consortium to you or any member of your family and/or promissory estoppel).
Notwithstanding the foregoing, you are not releasing any right of indemnification, or right to coverage as an insured under any contract or directors and officers liability insurance, you may have for any liabilities arising from your actions within the course and scope of your employment with the Company or within the course and scope of your role as a member of the Board of Directors and/or officer of the Company.  Also excluded from this Release are any claims which cannot be waived by law, including, without limitation, any rights you may have under applicable workers’ compensation laws and your right, if applicable, to file or participate in an investigative proceeding of any federal, state or local governmental agency. Nothing in this Release shall prevent you from filing, cooperating with, or participating in any proceeding or investigation before the Equal Employment Opportunity Commission, United States Department of Labor, the National Labor Relations Board, the Occupational Safety and Health Administration, the Securities and Exchange Commission or any other federal government agency, or similar state or local agency (“Government Agencies”), or exercising any rights pursuant to Section 7 of the National Labor Relations Act.  You further understand this Release does not limit your ability to voluntarily communicate with any Government Agencies or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, including providing documents or other information, without notice to the Company.  While this Release does not limit your right to receive an award for information provided to the Securities and Exchange Commission, you understand and agree that, you are otherwise waiving, to the fullest extent permitted by law, any and all rights you may have to individual relief based on any Claims that you have released and any rights you have waived by signing this Release.  If any Claim is not subject to release, to the extent permitted by law, you waive any right or ability to be a class or collective action representative or to otherwise participate in any putative or certified class, collective or multi-party action or proceeding based on such a Claim in which any of the Company Parties is a party.  This Release does not abrogate your existing rights under any Company benefit plan or any plan or agreement related to equity ownership in the Company; however, it does waive, release and forever discharge Claims existing as of the date you execute this Release pursuant to any such plan or agreement.
You are waiving, however, your right to any monetary recovery should any governmental agency or entity, such as the EEOC or the DOL, pursue any claims on your behalf. You acknowledge that you are knowingly and voluntarily waiving and releasing any rights you may have under the ADEA, as amended.  You also acknowledge that (i) the consideration given to you in exchange for the waiver and release in this Release is in addition to anything of value to
​

2

​
which you were already entitled, and (ii) that you have been paid for all time worked, have received all the leave, leaves of absence and leave benefits and protections for which you are eligible, and have not suffered any on-the-job injury for which you have not already filed a claim. You further acknowledge that you have been advised by this writing that:  (a) your waiver and release do not apply to any rights or claims that may arise after the execution date of this Release; (b) you have been advised hereby that you have the right to consult with an attorney prior to executing this Release; (c) you have twenty-one (21) days [in the event of a group release 21 days becomes 45 days] to consider this Release (although you may choose to voluntarily execute this Release earlier); (d) you have seven (7) days following your execution of this Release to revoke the Release; and (e) this Release shall not be effective until the date upon which the revocation period has expired unexercised, which shall be the eighth day after this Release is executed by you provided the Company has also executed the Release on or before that date (the “Release Date”).
4.Return of Company Property.  Within ten (10) days of the effective date of the termination of employment, you agree to return to the Company all Company documents (and all copies thereof) and other Company property then in existence that you have had in your possession at any time, including, but not limited to, Company files, notes, drawings, records, business plans and forecasts, financial information, specifications, computer-recorded information, tangible property (including, but not limited to, computers), credit cards, entry cards, identification badges and keys; and, any materials of any kind that contain or embody any proprietary or confidential information of the Company (and all reproductions thereof).  Receipt of the Severance described in paragraph 2 of this Release is expressly conditioned upon return of all such Company Property.
5.Confidentiality.  The provisions of this Release will be held in strictest confidence by you and will not be publicized or disclosed in any manner whatsoever; provided, however, that:  (a) you may disclose this Release in confidence to your immediate family; (b) you may disclose this Release in confidence to your attorney, accountant, auditor, tax preparer, and financial advisor; and (c) you may disclose this Release insofar as such disclosure may be required by law.  Notwithstanding the foregoing, nothing in this Release shall limit your right to voluntarily communicate with the Equal Employment Opportunity Commission, United States Department of Labor, the National Labor Relations Board, the Securities and Exchange Commission, other federal government agency or similar state or local agency or to discuss the terms and conditions of your employment with others to the extent expressly permitted by Section 7 of the National Labor Relations Act.
6.Proprietary Information, Inventions, Non-Competition and Non-Solicitation Obligations.  Both during and after your employment you acknowledge your continuing obligations under your Employee Confidential Information, Inventions, Non-Solicitation and Non-Competition Agreement (“Employee Proprietary Information Agreement”) not to use or disclose any confidential or proprietary information of the Company and to refrain from certain solicitation and competitive activities.  Confidential information that is also a “trade secret,” as defined by law, may be disclosed (A) if it is made (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. In addition, in
​

3

​
the event that you file a lawsuit for retaliation by the Company for reporting a suspected violation of law, you may disclose the trade secret to your attorney and use the trade secret information in the court proceeding, if you: (A) file any document containing the trade secret under seal; and (B) do not disclose the trade secret, except pursuant to court order.
7.[Note: The Company may, in its discretion, elect to include this provision] Non-Disparagement.  Both you and the Company agree not to disparage the other party, and the other party’s officers, directors, employees, shareholders and agents, in any manner likely to be harmful to them or their business, business reputation or personal reputation; provided that both you and the Company will respond accurately and fully to any question, inquiry or request for information when required by legal process.  The Company’s obligations under this Section are limited to company representatives with knowledge of this provision.  Notwithstanding the foregoing, nothing in this Release shall limit your right to voluntarily communicate with the Equal Employment Opportunity Commission, United States Department of Labor, the National Labor Relations Board, the Securities and Exchange Commission, other federal government agency or similar state or local agency or to discuss the terms and conditions of your employment with others to the extent expressly permitted by Section 7 of the National Labor Relations Act.
8.No Admission.  This Release does not constitute an admission by the Company of any wrongful action or violation of any federal, state, or local statute, or common law rights, including those relating to the provisions of any law or statute concerning employment actions, or of any other possible or claimed violation of law or rights.
9. Breach.  You agree that upon any material breach of this Release you will forfeit all amounts paid or owing to you under this Release.  Further, you acknowledge that it may be impossible to assess the damages caused by your material violation of the terms of paragraphs 4, 5, 6, and 7 of this Release and further agree that any threatened or actual material violation or breach of those paragraphs of this Release will constitute immediate and irreparable injury to the Company.  You therefore agree that any such breach of this Release is a material breach of this Release, and, in addition to any and all other damages and remedies available to the Company upon your breach of this Release, the Company shall be entitled to an injunction to prevent you from violating or breaching this Release.
10.Miscellaneous.  This Release, together with your Employee Proprietary Information Agreement, constitute the complete, final and exclusive embodiment of the entire agreement between you and the Company with regard to this subject matter.  It is entered into without reliance on any promise or representation, written or oral, other than those expressly contained herein, and it supersedes any other such promises, warranties or representations.  This Release may not be modified or amended except in a writing signed by both you and a duly authorized officer of the Company.  This Release will bind the heirs, personal representatives, successors and assigns of both you and the Company, and inure to the benefit of both you and the Company, their heirs, successors and assigns.  If any provision of this Release is determined to be invalid or unenforceable, in whole or in part, this determination will not affect any other provision of this Release and the provision in question will be modified by the court so as to be rendered enforceable.  This Release will be deemed to have been entered into and will be construed and enforced in accordance with the laws of the State of Maryland as applied to contracts made and performed entirely within the State of Maryland.
​
​

4

​
	GLYCOMIMETICS, INC.
	    
	​

	​
	​
	​

	​
	​
	​

	By: 
	​
	​
	​

	​
	​
	Date

	​
	​
	​

	EXECUTIVE
	​
	​

	​
	​
	​

	​
	​
	​

	Harout Semerjian
	​
	Date

​

Signature Page to Release Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00335-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00335-of-00352.parquet"}]]